Market Cap (In JPY)
17.32 Billion
Revenue (In JPY)
-
Net Income (In JPY)
-1.2 Billion
Avg. Volume
1.43 Million
- Currency
- JPY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 411.0-1512.0
- PE
- -
- EPS
- -
- Beta Value
- -0.536
- ISIN
- JP3244570002
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Takumi Kawabe M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.canbas.co.jp
- Ipo Date
- 2009-09-17
- Details
- CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
More Stocks
-
DSKY
-
ROU
-
UPRUniphar plc
UPR
-
TBPH
-
002491
-
6963ROHM Co., Ltd.
6963
-
CMPOWCompoSecure, Inc.
CMPOW
-
SYSSysGroup plc
SYS